Organogenesis Holding (NASDAQ: ORGO) reported Q2 EPS of ($0.10), $0.05 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $149.2 million versus the consensus estimate of $103.4 million.

GUIDANCE:

Organogenesis Holding sees FY 2025 revenue of $480-510 million, versus the consensus of $531.1 million.

The 2025 net product revenue guidance range assumes: Net product revenue from Advanced Wound Care products between $450.0 million and $475.0 million, a decrease of 1% to an increase of 5% year-over-year as compared to net product revenue of $453.6 million for the year ended December 31, 2024.

Net product revenue from Surgical & Sports Medicine products between $30.0 million and $35.0 million, an increase of 6% to 23% year-over-year as compared to net product revenue of $28.4 million for the year ended December 31, 2024.

Net income (loss) between $(6.4) million and $16.4 million and adjusted net income between $5.5 million and $28.3 million.

EBITDA between $6.2 million and $37.0 million and Adjusted EBITDA between $31.1 million and $61.9 million.

For earnings history and earnings-related data on Organogenesis Holding (ORGO) click here.